Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (19)
Juan Antonio García-Carmona & Sofia Pappa. (2023) Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal. Drug, Healthcare and Patient Safety 15, pages 113-123.
Read now
Read now
Laura M. Tidmore, Shellie L. Keast, Heidi C. Waters, Kristin L. Pareja, Terry Cothran & Grant H. Skrepnek. (2022) Readmissions, costs, and duration to subsequent outpatient visit after hospital discharge among Medicaid beneficiaries utilizing oral versus long-acting injectable antipsychotics in bipolar disorder or schizophrenia. Current Medical Research and Opinion 38:9, pages 1621-1630.
Read now
Read now
Gang Li, Alexander Keenan, Mehmet Daskiran, Maju Mathews, Isaac Nuamah, Camille Orman, Kruti Joshi, Arun Singh, Annabelle Godet, Katalin Pungor & Srihari Gopal. (2021) Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis. Patient Preference and Adherence 15, pages 2239-2248.
Read now
Read now
Martina Curto, Francesco Fazio, Martina Ulivieri, Serena Navari, Luana Lionetto & Ross J Baldessarini. (2021) Improving adherence to pharmacological treatment for schizophrenia: a systematic assessment. Expert Opinion on Pharmacotherapy 22:9, pages 1143-1155.
Read now
Read now
Xue Song, Antoine C. El Khoury, Matthew Brouillette, David Smith & Kruti Joshi. (2019) Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia. Journal of Medical Economics 22:11, pages 1105-1112.
Read now
Read now
Jennifer Munday, Mallik Greene, Eunice Chang, Ann Hartry, Tingjian Yan & Michael S. Broder. (2019) Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data. Current Medical Research and Opinion 35:7, pages 1231-1239.
Read now
Read now
Antoine C. El Khoury, Dominic Pilon, Laura Morrison, Nina Shak, Maude Vermette-Laforme, Tony B. Amos, Edward Kim & Patrick Lefebvre. (2019) The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia. Current Medical Research and Opinion 35:3, pages 395-405.
Read now
Read now
Martha Sajatovic, Ruth Ross, Susan N Legacy, Christoph U Correll, John M Kane, Faith DiBiasi, Heather Fitzgerald & Matthew Byerly. (2018) Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1. Neuropsychiatric Disease and Treatment 14, pages 1463-1474.
Read now
Read now
Chun-Hao Liu, Po-Hsin Tsai & Ching-Yen Chen. (2018) Discrepancy in Taiwanese psychiatrists’ preferences for long-acting injectable antipsychotics across facilities: a nationwide questionnaire survey. Neuropsychiatric Disease and Treatment 14, pages 429-433.
Read now
Read now
Wenjie Zhang, Tony B Amos, Stephen W Gutkin, Nicole Lodowski, Emma Giegerich & Kruti Joshi. (2018) A systematic literature review of the clinical and health economic burden of schizophrenia in privately insured patients in the United States. ClinicoEconomics and Outcomes Research 10, pages 309-320.
Read now
Read now
Janna Manjelievskaia, Tony B. Amos, Antoine C. El Khoury, Anna Vlahiotis, Ashley Cole & Paul Juneau. (2018) A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US. Journal of Medical Economics 21:12, pages 1221-1229.
Read now
Read now
Ahong Huang, Tony B. Amos, Kruti Joshi, Li Wang & Abigail Nash. (2018) Understanding healthcare burden and treatment patterns among young adults with schizophrenia. Journal of Medical Economics 21:10, pages 1026-1035.
Read now
Read now
Rhiannon Kamstra, Dominic Pilon, Patrick Lefebvre, Bruno Emond & Kruti Joshi. (2018) Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics. Current Medical Research and Opinion 34:8, pages 1377-1388.
Read now
Read now
Dominic Pilon, Kruti Joshi, Neeta Tandon, Marie-Hélène Lafeuille, Rhiannon L Kamstra, Bruno Emond & Patrick Lefebvre. (2017) Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic. Patient Preference and Adherence 11, pages 619-629.
Read now
Read now
Nesrin Dilbaz. (2015) New Targets for the Management of Schizophrenia. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 25:4, pages 407-428.
Read now
Read now
Kimberly M Shuler. (2014) Approaches to improve adherence to pharmacotherapy in patients with schizophrenia. Patient Preference and Adherence 8, pages 701-714.
Read now
Read now
Larry Alphs, Cynthia A Bossie, Dong-Jing Fu, Yi-Wen Ma & Jennifer Kern Sliwa. (2014) Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia. Expert Opinion on Pharmacotherapy 15:7, pages 1029-1042.
Read now
Read now
Gabriel Kaplan, Julio Casoy & Jacqueline Zummo. (2013) Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Preference and Adherence 7, pages 1171-1180.
Read now
Read now
Kathleen Lang, Victoria Federico, Erik Muser, Jordan Menzin & Joseph Menzin. (2013) Rates and predictors of antipsychotic non-adherence and hospitalization in Medicaid and commercially-insured patients with schizophrenia. Journal of Medical Economics 16:8, pages 997-1006.
Read now
Read now
Articles from other publishers (29)
Yifei Liu, Mark E. Patterson, Suman Sahil & Steven C. Stoner. (2023) Inpatient prescribing patterns of long-acting injectables and their oral or short-acting injectable equivalent formulations. Frontiers in Pharmacology 14.
Crossref
Crossref
Christoph U. Correll, Carmela Benson, Bruno Emond, Charmi Patel, Marie-Hélène Lafeuille, Dee Lin, Laura Morrison, Isabelle Ghelerter, Patrick Lefebvre & Panagiotis Mavros. (2023) Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies. Schizophrenia 9:1.
Crossref
Crossref
Ana Aliana Miron, Paula Simina Petric, Andreea Teodorescu, Petru Ifteni, Gabriela Chele & Andreea Silvana Szalontay. (2023) Benzodiazepines and Mood Stabilizers in Schizophrenia Patients Treated with Oral versus Long-Acting Injectable Antipsychotics—An Observational Study. Brain Sciences 13:2, pages 173.
Crossref
Crossref
Steven KheloussiJohn OberlinJrJrMadison TraugerNicholas D Testa. (2022) Clinical and economic impact of long-acting injectable antipsychotics in patients previously treated with short-acting oral antipsychotics. Journal of Managed Care & Specialty Pharmacy 28:10, pages 1130-1137.
Crossref
Crossref
Itay Perlstein, Avia Merenlender Wagner, Roberto Gomeni, Michael Lamson, Eran Harary, Ofer Spiegelstein, Attila Kalmanczhelyi, Ryan Tiver, Pippa Loupe, Micha Levi & Anna Elgart. (2022) Population Pharmacokinetic Modeling and Simulation of TV‐46000: A Long‐Acting Injectable Formulation of Risperidone. Clinical Pharmacology in Drug Development 11:7, pages 865-877.
Crossref
Crossref
Chizimuzo T.C. Okoli, Amani Kappi, Tianyi Wang, Andrew Makowski & Andrew T. Cooley. (2021) The effect of long‐acting injectable antipsychotic medications compared with oral antipsychotic medications among people with schizophrenia: A systematic review and meta‐analysis. International Journal of Mental Health Nursing 31:3, pages 469-535.
Crossref
Crossref
Tiffany Cristarella, Genaro Castillon, Jean‐François Nepveu & Yola Moride. (2022) Impact of schizophrenia relapse definition on the comparative effectiveness of oral versus injectable antipsychotics: A systematic review and meta‐analysis of observational studies. Pharmacology Research & Perspectives 10:1.
Crossref
Crossref
Vineet Dubey & Tulsi Ram Saini. (2022) Formulation development and pharmacokinetic studies of long acting in situ depot injection of risperidone. Brazilian Journal of Pharmaceutical Sciences 58.
Crossref
Crossref
Taishiro Kishimoto, Katsuhiko Hagi, Shunya Kurokawa, John M Kane & Christoph U Correll. (2021) Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies. The Lancet Psychiatry 8:5, pages 387-404.
Crossref
Crossref
Dee Lin, Philippe Thompson-Leduc, Isabelle Ghelerter, Ha Nguyen, Marie-Hélène Lafeuille, Carmela Benson, Panagiotis Mavros & Patrick Lefebvre. (2021) Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis. CNS Drugs 35:5, pages 469-481.
Crossref
Crossref
Andrea Fiorillo, Stefano Barlati, Antonello Bellomo, Giulio Corrivetti, Giuseppe Nicolò, Gaia Sampogna, Valentina Stanga, Franco Veltro, Giuseppe Maina & Antonio Vita. (2020) The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: a clinical review. Annals of General Psychiatry 19:1.
Crossref
Crossref
Serafeim Papakostas, Ayesha Dar & Lawrence Ratna. (2020) Sociodemographic Factors and Medication Administration Factors Affecting Re – Hospitalization in Patients with Schizophrenia – Spectrum Disorders. Psychiatric Quarterly 91:4, pages 1363-1369.
Crossref
Crossref
Su‐Chen Fang, Ding‐Lieh Liao, Cheng‐Yi Huang, Chun‐Chi Hsu, Shu‐Li Cheng & Yu‐Hsuan J. Shao. (2020) The effectiveness of long‐acting injectable antipsychotics versus oral antipsychotics in the maintenance treatment of outpatients with chronic schizophrenia. Human Psychopharmacology: Clinical and Experimental 35:3.
Crossref
Crossref
Antoine C. El KhouryDominic PilonLaura MorrisonNina Shak, Amanda LlanezaEdward KimPatrick Lefebvre. (2020) Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia. Journal of Managed Care & Specialty Pharmacy 26:2, pages 176-185.
Crossref
Crossref
Qian Cai, Charmi Patel, Edward Kim, Nancy Connolly, Ozgur Tunceli & Antoine C. El Khoury. (2019) Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study. Advances in Therapy 36:4, pages 858-869.
Crossref
Crossref
Ankit Shah, Lin Xie, Furaha Kariburyo, Qisu Zhang & Mugdha Gore. (2018) Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics. Advances in Therapy 35:11, pages 1994-2014.
Crossref
Crossref
Taishiro Kishimoto, Katsuhiko Hagi, Masahiro Nitta, Stefan Leucht, Mark Olfson, John M Kane & Christoph U Correll. (2018) Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies. Schizophrenia Bulletin 44:3, pages 603-619.
Crossref
Crossref
Jeffrey P. Anderson, Zeynep Icten, Veronica Alas, Carmela Benson & Kruti Joshi. (2017) Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations. BMC Psychiatry 17:1.
Crossref
Crossref
Dominic Pilon, Neeta Tandon, Marie-Hélène Lafeuille, Rhiannon Kamstra, Bruno Emond, Patrick Lefebvre & Kruti Joshi. (2017) Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics. Clinical Therapeutics 39:10, pages 1972-1985.e2.
Crossref
Crossref
Flore Decuypere, Jan Sermon, Paul Geerts, Tom R. Denee, Cedric De Vos, Bart Malfait, Mark Lamotte & Cornelis L. Mulder. (2017) Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study. PLOS ONE 12:6, pages e0179049.
Crossref
Crossref
Steven G. Potkin, Rimal Bera, Anna Eramo & Gina Lau. (2017) A Pilot Study of Cultural/Racial Differences in Patient Perspectives on Long-Acting Injectable Antipsychotics for the Treatment of Schizophrenia. Clinical Schizophrenia & Related Psychoses 10:4, pages 211-221.
Crossref
Crossref
Georgia L. Stevens, Gail Dawson & Jacqueline Zummo. (2015) Clinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia. Early Intervention in Psychiatry 10:5, pages 365-377.
Crossref
Crossref
Steven C. Marcus, Jacqueline Zummo, Amy R. Pettit, Jeffrey Stoddard & Jalpa A. Doshi. (2015) Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge. Journal of Managed Care & Specialty Pharmacy 21:9, pages 754-769.
Crossref
Crossref
James Paul Smith & Oliver Rudolf Herber. (2014) Ethical issues experienced by mental health nurses in the administration of antipsychotic depot and long‐acting intramuscular injections: A qualitative study. International Journal of Mental Health Nursing 24:3, pages 222-230.
Crossref
Crossref
Peter Bosanac & David Jonathan Castle. (2018) Why are long-acting injectable antipsychotics still underused?. BJPsych Advances 21:2, pages 98-105.
Crossref
Crossref
Ivana Simić-Medojević & Marija Burgić-Radmanović. (2015) Quality of life of schizophrenic patients with or without depot neuroleptics. Scripta Medica 46:1, pages 60-65.
Crossref
Crossref
Sofia Brissos, Miguel Ruiz Veguilla, David Taylor & Vicent Balanzá-Martinez. (2014) The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Therapeutic Advances in Psychopharmacology 4:5, pages 198-219.
Crossref
Crossref
Steven Potkin, Rimal Bera, Donna Zubek & Gina Lau. (2013) Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. BMC Psychiatry 13:1.
Crossref
Crossref
Therese M. Grant, Natalie Novick Brown, Dan Dubovsky, Joanne Sparrow & Richard Ries. (2013) The Impact of Prenatal Alcohol Exposure on Addiction Treatment. Journal of Addiction Medicine 7:2, pages 87-95.
Crossref
Crossref